Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment Centers

StemVacs Immunotherapy Platform for Prostate Cancer

Download Rationale as PDF

StemVacs is a platform for antigen-nonspecific immune modulatory treatment that can be utilized as a monotherapy or as a combination with antigen-specific modalities such as peptide or protein-based vaccines.

StemVacs is, therefore, a subcutaneously administered vaccine comprised of immune stimulatory peptides resembling cancer stem cell-specific proteins.

StemVacs is now available as a treatment option at the Pan American Cancer Treatment Center in Tijuana, Mexico for stages 1-4 breast and prostate cancers.

Immunotherapy as an Alternative to Watchful Waiting

Early Stage Prostate Cancer: Because prostate cancer often grows very slowly, some men (especially those who are older or have other serious health problems) might never need treatment for their prostate cancer. Instead, their doctors usually recommend approaches known as watchful waiting. If you have elevated PSA but slow-growing prostate cancer, does it make sense to play “Russian Roulette” with your health? Currently, the only medical intervention that is available to patients with early-stage prostate cancer who do not want to “wait” is taking finasteride, which although has been shown to decrease the overall incidence, the patients that developed aggressive cancer had higher aggression when taking finasteride as compared to controls [1].

Immunotherapy Instead of Waiting: One promising treatment that we are developing and offering at the Pan Am Cancer Treatment Center, for patients who are “watchfully waiting” is the application of an immunotherapy that specifically trains the immune system to attack cancer.

Immunotherapy has been approved by the FDA for treatment of late-stage prostate cancer in the form of the cellular drug Provenge [2]. This drug is comprised of a type of immune system cell, termed “dendritic cell” that is generated from the blood of patients.

It has the capacity to activate other immune cells in the body to attack proteins found on prostate-derived cells. Since prostate cancer cells possess prostate proteins, the immune system of patients treated with Provenge begins attacking prostate cancer cells not only in the prostate but all throughout the body [3]. One of the main reasons why Provenge is not utilized in the United States for early-stage prostate cancer is its high costs [4].

This is very unfortunate because in the early stages of prostate cancer the immune system of the patient is still relatively intact, thus offering a much higher chance of success [5, 6].

With the advantage of 10 years of experience in cellular processing and manufacturing, as well as a partnership with Key Opinion Leaders in the area of dendritic cell therapy, the Pan Am Cancer Treatment Center offers a novel way of dealing with early-stage prostate cancer.

Instead of  “watchful waiting” or taking drugs that potentially increase the possibility of developing aggressive tumors, we offer a prostate cancer immunotherapeutic based on the same scientific principles as Provenge except for increased efficacy and lower price.

Rationale for Immunotherapy: The immune system is an ever-vigilant defense against bacterial, viral and parasitic infections, as well as against cancer [7]. Early studies demonstrated that some cancer patients whose immune systems are activated as a result of bacterial infections undergo remissions. Importantly, patients who have a chronically low level of immune activity are characterized by staggeringly high incidence of cancer [8].

Further support for an active role of the immune system in protecting the body against cancer comes from recent clinical trials in which a class of immune system stimulatory drugs termed “checkpoint inhibitors” have achieved previously unheard of results in cancers resistant to treatment such as advanced prostate cancer [9].

It is well recognized that various types of cancers possess an incrementally higher level of ability to suppress the immune system the more advanced the cancer is. For example, in prostate cancer patients, those possessing a higher Gleason score suffer from an increased suppression of immune function [10, 11].

Accordingly, augmentation of anticancer responses by introducing immunotherapy earlier in the pathogenesis of cancer progression increases the probability of success.

NanoStilbene: Patented Augmenter of Cancer Immunotherapy

NanoStilbene, a nanoparticle formulation of pterostilbene, is covered for use in cancer immunotherapy under the Company’s issued U.S. Patent No.: 9,682,047 and is included as part of the Prostate Cancer Protocol with StemVacs.

NanoStilbene is an easily absorbed nanoemulsion of nanoparticle pterostilbene in the range of

75-100nm at a concentration of 30 milligrams per milliliter. The pterostilbene placed in a nanoemulsion droplet is free from air, light, and hard environment; therefore, as a delivery system, nanoemulsion can not only improve the bioavailability of pterostilbene but also protect it from oxidation and hydrolysis, while it possesses an ability of sustained release at the same time.

Therapeutic uses of nanotechnology typically involve the delivery of small-molecule drugs, peptides, proteins, and nucleic acids. Nanoparticles have advanced pharmacological effects compared with the therapeutic entities they contain. Active intracellular delivery and improved pharmacokinetics and pharmacodynamics of drug nanoparticles depend on various factors, including their size and surface properties.

Nanoparticle therapeutics is an emerging treatment modality in cancer and other inflammatory disorders. The National Cancer Institute has recognized nanotechnology as an emerging field with the potential to revolutionize modern medicine for detection, treatment, and prevention of cancer.


At present, the only options available for patients with early-stage prostate cancer is waiting or taking drugs that potentially could increase aggressiveness.

The Pan Am Cancer Treatment Center has generated an economical means of generating the same immunotherapy as the FDA approved Provenge, however specific to targeting early-stage cancer.

The Pan American Cancer Treatment Center is located a few miles south of sunny San Diego, in Tijuana, Mexico. The Pan Am facilities are state of art and offer access to cutting-edge cancer immunotherapies outside of clinical trials. After we receive you in San Diego, you will travel by air-conditioned transportation to our new and modern treatment center, where you will have access to cellular, small molecule, and protein therapies through accelerated means.


  1. 1.…/finasteride-reduces-low-grade.
  2. 2. Patel, P.H. and D.R. Kockler, Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother, 2008. 42(1): p. 91-8.
  3. 3. Buonaguro, L., et al., Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol, 2011. 18(1): p. 23-34.
  4. 4. Jaroslawski, S. and M. Toumi, Sipuleucel-T (Provenge((R)))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. BioDrugs, 2015. 29(5): p. 301-7.
  5. 5. Gray, A., et al., A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev, 2008. 222: p. 316-27.
  6. 6. Miller, A.M., et al., CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol, 2006. 177(10): p. 7398-405.
  7. 7. Mohme, M., S. Riethdorf, and K. Pantel, Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat Rev Clin Oncol, 2016.
  8. 8. Soulillou, J.P. and M. Giral, Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation, 2001. 72(12 Suppl): p. S89-93.
  9. 9. Tsiatas, M. and P. Grivas, Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med, 2016. 4(14): p. 270.
  10. 10. de Charry, F., et al., Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases. Clin Genitourin Cancer, 2016. 14(3): p. 210-217 e1.
  11. 11. Shimura, S., et al., Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res, 2000. 60(20): p. 5857-61.